Summary
Fifty-seven patients with renal cancer were treated with AZQ, utilizing one of three IV push schedules. Only one partial response was seen in 55 evaluable patients, and considerable myelosuppression was encountered. Gastrointestinal toxicity was more severe in those patients who had received prior treatment. At these higher doses AZQ is deemed an inactive agent in patients with renal cell carcinoma, at least when the drug is administered as a push schedule.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Driscoll JS, Hazard GF Jr, Wood HB Jr, Goldin A: Structure-antitumor activity relationships among quinone derivatives. Cancer Chemother Rep 4 (Part 2):1–363, 1974
Bender JF, Grillo-Lopez AJ, Posada JG Jr: Diasiquone (AZQ). Invest N Drugs 1:71–84, 1983
Hansen M, Gallmeier WM, Vermorken J, Holdener E, Hansen HH, Renard J, Rozencweig M: Phase II trial of Diaziquone in advanced renal adenocarcinoma. Cancer Treat Rep 68:1055–1056, 1984
Taylor SA, Eyre H: Phase II trial of AZQ (NSC 182986) in patients with primary (1 °) central nervous system malignancies (CNSM): A Southwest Oncology Group Study. J Neuro-Oncology 2:288, 1984
Schilsky RL, Kelley JA, Ihde DC, Howser DM, Cordes RS, Young RC: Phase I trial and pharmacokinetics of aziridinyl-benzoquinone (NSC 182986) in humans. Cancer Res 42:1582–1586, 1982
Frytak S, Eagan RT, Ames MM, Creagan ET, Nichols WC: Phase I study of diaziquone. Cancer Treat Rep 68:975–978, 1984